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at an increased risk of osteonecrosis. Thus, we sought to 
investigate surgical specimens after sSBRT and primary 
SBRT (pSBRT) regarding histopathological changes. 
Material and Methods  
We retrospectively assessed 704 patients who were 
treated with sSBRT (69.6%) or pSBRT (30.4%) for spinal 
bone metastases at 7 international centers between 2006 
and 2012. 30 patients underwent salvage surgery after 
SBRT. In 23 cases, the histopathological reports were 
available for review. Clinical and histopathological 
findings were statistically analyzed and compared 
between the two groups. 
Results  
Mean time to surgery after sSBRT/pSBRT was 8.3/10.3 
months (p=.64). Reasons for salvage surgery after SBRT 
included pain (sSBRT/pSBRT: 12.5%/71.4%, p=.25), 
fractures (sSBRT/pSBRT: 37.5%/28.6%, p=.68) and 
neurological symptoms (sSBRT/pSBRT: 68.8%/42.9%, 
p=.24). Radiological tumor progression after sSBRT/pSBRT 
was seen in 71.4%/42.9% (p=.20). Histopathological 
findings were similar in specimens from patients after 
sSBRT and pSBRT. Most specimens displayed 
viable/proliferative tumor (sSBRT/pSBRT: 62.5%/71.4%, 
p=.68 and 56.3%/57.1%, p=.97). Few specimens showed 
soft tissue necrosis (sSBRT/pSBRT: 20%/28.6%, p=.66), 
osteonecrosis (sSBRT/pSBRT: 14.3%/16.7%, p=.89) or bone 
marrow fibrosis (sSBRT/pSBRT: 42.9%/33.3%, p=.69). 
Tumor bed necrosis was more common after sSBRT 
(81.3%/42.9%, p=.066). Radiological tumor progression 
correlated with viable/proliferative tumor 
(p=.03/p=.006) and tumor bed necrosis (p=.03). Fractures 
were increased with bone marrow fibrosis (p=.07), but 
not with osteonecrosis (p=.53) or soft tissue necrosis 
(p=.19). Neurological symptoms were common in patients 
with radiological tumor progression (p=.07), but not in 
those with fractures (p=.18). In both, patients with tumor 
progression (p=.72) and those with pathological fractures 
(p=.19), the occurrence or progression of pain was 
independent of the radiological findings. 
Conclusion  
Histopathological changes were similar after sSBRT and 
pSBRT. Neurological symptoms were chiefly attributable 
to tumor progression. Pathological fractures were neither 
associated with osteonecrosis nor tumor progression. 
Evidence of viable tumor in most specimens calls for an 
aggressive treatment with sSBRT and pSBRT. 
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Purpose or Objective  
To investigate the effectiveness and safety of spinal 
stereotactic ablative radiotherapy (SABR) in spinal 
metastasis with epidural spinal cord compression (ESCC). 
Material and Methods  
From 2013 to 2016, 149 spine metastases of 10 5 
patients who were treated with single-fraction (12–24 Gy) 
spinal SABR were reviewed. ESCC status was stratified 
according to the Bilsky grade (0, bone-only; 1, epidural 
impingement; 2, cord compression with visible 
cerebrospinal fluid (CSF); and 3, no CSF visible around 
the cord). Local progression (LP) and vertebral 
compression fracture (VCF) rates after SABR were 
evaluated by using cumulative incidence function in 
competing risks data and univariate and multivariate 
competing-risk regression analyses. 
 
 
Results  
Median follow-up was 8.8 months (0.5–56.6 months). One-
year cumulative incidence of LP in the Bilsky grade 0 (n = 
80), 1 (n = 39), 2 (n = 21), and 3 (n = 9) groups were 3.0%, 
8.4%, 0%, and 24.9%. On multivariate competing-risk 
regression analysis, ESCC (the Bilsky grade 2 and 3) did 
not increase LP rate (No LP in the grade 2 group; 
subdistribution hazard ratio [SHR] of the grade 3 
compared to the grade 0, 4.301, 95% confidence interval 
[CI], 0.386-47.956, p = 0.236), while small tumor extent 
(p < 0.001), breast origin (p < 0.001), blastic lesion (p < 
0.001), and radiation dose > 20 Gy (p < 0.001) were 
favorable prognostic factors for LP. One-year cumulative 
incidence of VCF in the Bilsky grade 0, 1, 2, and 3 groups 
were 7.5%, 5.9%, 19.1%, and 13.6%, respectively. 
Multivariate competing-risk regression analysis for VCF 
demonstrated that ESCC may increase the risk of VCF (HR 
of the Bilsky grade 2 compared to the grade 0, 5.368, 95% 
CI 1.129–25.530, p = 0.035; HR of the grade 3, 2.215, 95% 
CI 0.269–18.248, p = 0.460). Complete or partial pain 
response rates after SABR were 79%, 78%, 53%, and 63% in 
the Bilsky grade 0, 1, 2, and 3, respectively (p = 0.008). 
No grade ≥ 3 side effect was observed. 
  
 
Conclusion  
Spinal SABR for the patients with ESCC did not increase 
LP rate and grade 3 or more neurotoxicity probability 
with moderate VCF and pain response rates. Spinal SABR 
may serve as an effective and safe treatment option for 
the patients with ESCC. 
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Purpose or Objective  
Palliative radiotherapy for bone metastases is offered in 
patients with a life expectancy of at least 4 weeks and 
provides improved pain control in 60%. Short time to pain 
response (median 2-3 weeks) and improved health-
related quality of life (HRQoL) in responders has 
increased radiotherapy use in those with expected short 
survival. In general, HRQoL deteriorates towards death. It 
is not clear, if in this period, the association between 
pain response and HRQoL is maintained. This study 
investigated the relationships between survival, pain 
response and QoL outcomes. 
Material and Methods  
Weekly questionnaires collected from the Dutch Bone 
Metastasis Study cohort (1996-1998) in the first 12 weeks 
following radiotherapy were used to assess pain response 
(using International consensus guidelines), and HRQoL in 
relation to survival. In this trial, in 1157 patients, 8 Gray 
was equivalent in terms of pain response to 24 Gray in 6 
fractions. A random-effects linear regression model was 
used to assess the relationship between each reported 
pain response and change in HRQoL (using the EQ-5D 
visual analogue scale). To investigate the relationship 
between pain reduction and probability of change from 
baseline in EQ-5D domain responses with varying survival, 
we used an ordered logistic regression model. All models 
included all available weekly responses, clustered within 
patients and adjusted for baseline and time varying co-
variables. The models were used to predict outcomes in 
relation to survival. 
Results  
Pain response was less likely in those with shorter 
survival: 17%, 45%, 54% and 74% of patients surviving <4 
weeks, 4-8 weeks, 8-12 weeks and >12 weeks respectively 
reported response (p<0.001). Improvement in EQ-VAS was 
associated with age >65 (p=0.02), pain response 
(p<0.001) and increasing survival (p<0.001) (Fig 1), whilst 
pain progression (p<0.001), re-treatment (p<0.001), 
higher baseline EQ-VAS (p<0.001) and presence of other 
bony metastases (p=0.005) were associated with less 
improvement in EQ-VAS. Treatment site, baseline 
performance status and visceral/brain metastases had no 
significant association with change in EQ-VAS. The 
probability of improvement in all EQ-5D domains 
decreased with reducing survival time (p<0.001). This was 
most marked in mobility, self-care and activity domains 
where those with pain response had a higher predicted 
probability of deterioration than improvement if survival 
was less than 12 weeks (Fig 2).  
 
 
 
Conclusion  
Pain reduction in the first 12 weeks following palliative 
radiotherapy for bone metastases was less likely for 
patients with limited survival. Additionally, pain response 
was associated with significantly lower improvements in 
global HRQoL and lower probability of improvement in 
other domains of HRQoL as measured by the EQ5D in 
these patients. Both clinicians and patients should be 
aware of these findings when considering radiotherapy 
for painful bone metastases near the end of life to ensure 
that expectations of treatment benefits are realistic.  
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Purpose or Objective  
SBRT of lymph node oligometastases on the 1.5T MRI-
Linac may allow for the use of smaller PTV margins and 
can incorporate daily patient anatomy. This opens up 
opportunities for dose escalation and hypofractionation 
towards a higher biologically equivalent dose (BED) 
associated with improved local tumour control. The aim 
of this study is to investigate the feasibility of dose 
escalated and hypofractionated fractionation schemes for 
treatment on the 1.5T MRI-Linac. 
Material and Methods  
Patient imaging data and delineations from five patients 
with advanced cervical cancer with a combined total of 
17 lymph nodes in the pelvic and para-aortic region were 
used for simulating treatment of lymph node 
oligometastases using SBRT. Three treatment plans were 
created for each lymph node with a prescribed dose of 
5x7Gy, 3x12Gy and 1x24Gy using a 3mm isotropic PTV 
margin. Additionally a 1x24Gy plan was created using a 
